A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 -dose Regimen of V114 in Healthy Infants (PNEU-PED)

Project: Other project

StatusActive
Effective start/end date4/25/194/24/21

Funding

  • Merck Sharp & Dohme Corporation: $4,615.38